Microbot Medical (NASDAQ:MBOT) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01, Bloomberg Earnings reports.
Shares of MBOT stock opened at $0.85 on Thursday. Microbot Medical has a 1 year low of $0.85 and a 1 year high of $0.87.
Several equities research analysts recently issued reports on the company. ValuEngine upgraded Microbot Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Ladenburg Thalmann assumed coverage on Microbot Medical in a research note on Wednesday, January 31st. They issued a “buy” rating and a $1.75 price target for the company.
Microbot Medical Company Profile
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company's product candidates include Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and TipCAT, a semi-disposable, flexible, and self-propelled endoscope for use in colonoscopy procedures, as well as ViRob, a revolutionary autonomous crawling micro-robot technology, which can be controlled remotely or within the body.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.